Good upturn, however AT1 still have some ground to make up.
Additional upturn may result from some of the following;
1. Revised agreement with Access Bio to increase supply
2. Lumos obtain FDA approval for FebriDx
3. Rapid Antigen Test gets some traction in Aus/NZ
Hopefully soon.
- Forums
- ASX - By Stock
- AT1
- Ann: Access Bio receives FDA clearance for COVID-19 antibody test
Ann: Access Bio receives FDA clearance for COVID-19 antibody test, page-20
Featured News
Add AT1 (ASX) to my watchlist
(20min delay)
|
|||||
Last
2.2¢ |
Change
0.001(4.76%) |
Mkt cap ! $14.06M |
Open | High | Low | Value | Volume |
2.3¢ | 2.5¢ | 2.2¢ | $24.03K | 1.041M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 541875 | 2.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.3¢ | 699206 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 541875 | 0.021 |
11 | 821549 | 0.020 |
7 | 420742 | 0.019 |
4 | 430053 | 0.018 |
4 | 910888 | 0.017 |
Price($) | Vol. | No. |
---|---|---|
0.023 | 699206 | 3 |
0.024 | 170000 | 3 |
0.025 | 1332555 | 4 |
0.026 | 748949 | 3 |
0.027 | 643000 | 2 |
Last trade - 15.56pm 13/11/2024 (20 minute delay) ? |
Featured News
AT1 (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online